MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Contact Us

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

Tepotinib Journal Publications

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.

Bladt | Cancers 2014 6:1736-52.

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors.

Bladt | Clin Cancer Res. 2013 19:2941-51.

Phase 1b/2 Trial of Tepotinib in Sorafenib Pretreated Advanced Hepatocellular Carcinoma with MET Overexpression.

Decaens | British Journal of Cancer. 2021 Apr 6:1-0.

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.

Falchook | Clin Cancer Res. 2020 Mar 15;26(6):1237-1246.

The Selective c-Met Inhibitor Tepotinib Can Overcome Epidermal Growth Factor Receptor Inhibitor Resistance Mediated by Aberrant c-Met Activation in NSCLC Models.

Friese-Hamim | Am J Cancer Res. 2017 Apr 1;7(4):962-972.

Open-Label, Single-Center, Phase I Trial to Investigate the Mass Balance and Absolute Bioavailability of the Highly Selective Oral MET Inhibitor Tepotinib in Healthy Volunteers.

Johne | Invest New Drugs. 2020 Oct;38(5):1507-1519.

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.

Le | Clin Cancer Res. 2021 Nov 17.

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

Paik | N Engl J Med. 2020 Sep 3;383(10):931-943.

Randomised Phase 1b/2 Trial of Tepotinib vs Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma with MET Overexpression.

Ryoo | British Journal of Cancer. 2021 May 10:1-9.

Tepotinib Plus Gefitinib in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with MET Overexpression or MET Amplification and Acquired Resistance to Previous EGFR Inhibitor (INSIGHT study): An Open-Label, Phase 1b/2, Multicentre, Randomised Trial.

Wu | Lancet Respir Med. 2020 Nov;8(11):1132-1143.

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options:

Tepotinib Journal Publications

Cookie Disclaimer

Welcome to EMD Serono Medical Information!